CTOs on the Move

Nanogen, Inc.

www.nanogen.com

 
Nanogen, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.nanogen.com
  • 10398 Pacific Center Ct
    San Diego, CA USA 92121
  • Phone: 858.410.4600

Executives

Name Title Contact Details

Similar Companies

US Ecology

US Ecology, Inc. is a leading North American provider of environmental services to commercial and government entities. The Company addresses the complex waste management needs of its customers, offering treatment, disposal and recycling of hazardous and radioactive waste, as well as a wide range of complementary field and industrial services. US Ecology's focus on safety, environmental compliance, and customer service, enables us to effectively meet the needs of our customers and to build long-lasting relationships. Headquartered in Boise, Idaho, with operations in the United States, Canada and Mexico, the Company has been protecting the environment since 1952. To protect and improve our environment by safely providing reliable environmental and industrial service solutions to commercial, industrial and government customers.

GeneGo bioinformatics software

GeneGo bioinformatics software, Inc. is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aquabio

Aquabio is a Arlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tissue Gnostics

Tissue Gnostics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CARsgen

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.